Trial · NCT00457366
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
NCT00457366, Phase 4, Completed, University of Southern California; results first posted 2019-07-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room. Trials, record NCT00457366. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00457366
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
- NCT number
- NCT00457366
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 72 participants, actual
- Lead sponsor
- University of Southern California
- Conditions
- Agitation
- Interventions
- Quetiapine, Haloperidol, Lorazepam, Cogentin
- First posted
- 2007-04-06
- Last updated
- 2019-07-26
- Results first posted
- 2019-07-05
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. | Two hours | The PANSS-EC is the Positive and Negative Syndrome Score - Excited Component, which includes 5 items (excitement, hostility, tension, uncooperative, poor impulse control), which are rated from 1 (not present) to 7 (extremely severe); scores range from 5 to 35; mean scores ≥ 20 clinically correspond to severe agitation. This set of items detects differences between drug and placebo when evaluating acute agitation and aggression in psychiatric patients with different psychiatric pathologies (Montoya, A; Villadares, A; Lizan, L, et al., 2011). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. | Two hours | 34 patients received the Cocktail, but 4 of these were excluded from the analysis because they had only demographic data and no clinical outcome data. A total of 38 patients received Quetiapine; all were included in the analysis. | score on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. | Cocktail | -11.0 | Standard Error 0.82 | score on a scale | |
| Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. | Quetiapine | -11.5 | Standard Error 0.69 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Quetiapine | 40 | |
| Overall Study | STARTED | Cocktail Consisting of Haloperidol, Lorazepam, Cogentin | 32 | |
| Overall Study | COMPLETED | Quetiapine | 40 | |
| Overall Study | COMPLETED | Cocktail Consisting of Haloperidol, Lorazepam, Cogentin | 32 | |
| Overall Study | NOT COMPLETED | Quetiapine | 0 | |
| Overall Study | NOT COMPLETED | Cocktail Consisting of Haloperidol, Lorazepam, Cogentin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Quetiapine | ||
| Total, all-cause mortality | Cocktail | ||
| Total, other adverse events | Quetiapine | 0 | 40 |
| Total, other adverse events | Cocktail | 0 | 32 |
| Total, serious adverse events | Quetiapine | 0 | 40 |
| Total, serious adverse events | Cocktail | 0 | 32 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Quetiapine vs Cocktail: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00457366
GET https://conductscience.org/api/trials/v1/NCT00457366/registered